Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NOK 4.59
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. The company was founded in 2017 and is headquartered in Oslo, Norway.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, overvalued on P/F
Data is available to registered users only
Target Price
The average target price of TRMED.OL is 3.5 and suggests 24% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to
Data is available to registered users only
Buy
Sell